PT  - JOURNAL ARTICLE
AU  - MASAHIDE KUROKI
AU  - KEN HACHIMINE
AU  - HIRONORI ABE
AU  - HIROTOMO SHIBAGUCHI
AU  - MOTOMU KUROKI
AU  - SHIN-ICHI MAEKAWA
AU  - JUN YANAGISAWA
AU  - TETSUSHI KINUGASA
AU  - TOSHIHIRO TANAKA
AU  - YUICHI YAMASHITA
TI  - Sonodynamic Therapy of Cancer Using Novel Sonosensitizers
DP  - 2007 Nov 01
TA  - Anticancer Research
PG  - 3673--3677
VI  - 27
IP  - 6A
4099  - http://ar.iiarjournals.org/content/27/6A/3673.short
4100  - http://ar.iiarjournals.org/content/27/6A/3673.full
SO  - Anticancer Res2007 Nov 01; 27
AB  - Sonodynamic therapy (SDT) of cancer is based on preferential uptake and/or retention of a sonosensitizing drug (sonosensitizer) in tumor tissues and subsequent activation of the drug by ultrasound irradiation. Ultrasound can penetrate deeply into tissues and can be focused into a small region of a tumor to activate a sonosensitizer. This is a unique advantage in the non-invasive treatment of nonsuperficial tumors when compared to laser light used for photodynamic therapy. Recently, it has been found that photochemically active porphyrins also show significant antitumor effects when activated with ultrasound. The mechanism of sonodynamic action has been suggested to involve photoexcitation of the sensitizer by sonoluminescent light, with subsequent formation of singlet oxygen. This mini-review provides a brief overview of the following four sonosensitizers useful in SDT: i) a homogeneous complex of oligomers of hematoporphyrin, Photofrin II; ii) a gallium porphyrin complex, ATX-70; iii) a hydrophilic chlorin derivative, ATX-S10, and iv) a novel porphyrin derivative devoid of photosensitivity, DCPH-P-Na(I). Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved